Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

Clinical trial NCT07511504 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07511504
Sponsor: OHSU Knight Cancer Institute
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced Hepatocellular Carcinoma Stage III Hepatocellular Carcinoma AJCC v8 Stage IV Hepatocellular Carcinoma AJCC v8 Unresectable Hepatocellular Carcinoma

Start date: 2026-04-02
Primary completion: 2027-08-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.